Corvus Pharmaceuticals (CRVS) Competitors $4.17 -0.18 (-4.14%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$4.21 +0.04 (+1.06%) As of 07/15/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. AUPH, ARDX, ELVN, VERV, NAGE, DYN, CDTX, COLL, BGM, and PHVSShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Niagen Bioscience (NAGE), Dyne Therapeutics (DYN), Cidara Therapeutics (CDTX), Collegium Pharmaceutical (COLL), BGM Group (BGM), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Its Competitors Aurinia Pharmaceuticals Ardelyx Enliven Therapeutics Verve Therapeutics Niagen Bioscience Dyne Therapeutics Cidara Therapeutics Collegium Pharmaceutical BGM Group Pharvaris Corvus Pharmaceuticals (NASDAQ:CRVS) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Is CRVS or AUPH more profitable? Aurinia Pharmaceuticals has a net margin of 16.11% compared to Corvus Pharmaceuticals' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 14.27% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -24.04% -13.90% Aurinia Pharmaceuticals 16.11%14.27%9.93% Which has preferable valuation & earnings, CRVS or AUPH? Aurinia Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$62.29M-$0.98-4.26Aurinia Pharmaceuticals$235.13M5.17$5.75M$0.2832.11 Which has more volatility & risk, CRVS or AUPH? Corvus Pharmaceuticals has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Does the media refer more to CRVS or AUPH? In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Aurinia Pharmaceuticals' score of 1.20 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Corvus Pharmaceuticals Very Positive Aurinia Pharmaceuticals Positive Do institutionals and insiders believe in CRVS or AUPH? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 31.3% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer CRVS or AUPH? Corvus Pharmaceuticals presently has a consensus target price of $15.00, suggesting a potential upside of 259.71%. Aurinia Pharmaceuticals has a consensus target price of $11.50, suggesting a potential upside of 27.92%. Given Corvus Pharmaceuticals' higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAurinia Pharmaceuticals beats Corvus Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$296.54M$2.96B$5.62B$9.29BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-4.2620.2228.5719.58Price / SalesN/A290.24423.3293.40Price / CashN/A43.1536.0257.93Price / Book8.187.568.135.54Net Income-$62.29M-$55.11M$3.24B$257.73M7 Day Performance-0.24%3.81%0.16%-0.08%1 Month Performance-2.11%11.60%5.95%8.09%1 Year Performance78.97%-2.11%26.09%13.02% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.8458 of 5 stars$4.17-4.1%$15.00+259.7%+108.5%$296.54MN/A-4.2630Positive NewsAUPHAurinia Pharmaceuticals3.0045 of 5 stars$7.47-1.6%$11.50+53.9%+58.6%$1.03B$235.13M26.68300ARDXArdelyx4.0655 of 5 stars$4.35+1.9%$10.89+150.3%-24.4%$1.02B$333.61M-19.7790ELVNEnliven Therapeutics2.7988 of 5 stars$19.59-5.5%$41.20+110.3%-13.7%$1.02BN/A-10.2050VERVVerve Therapeutics3.0219 of 5 stars$11.16-1.1%$14.57+30.6%+53.9%$1.01B$59.61M-5.29110NAGENiagen Bioscience0.7343 of 5 stars$12.44-2.1%$19.50+56.8%N/A$1.00B$99.60M73.18120DYNDyne Therapeutics4.0105 of 5 stars$8.18-6.6%$41.13+402.8%-80.9%$995.72MN/A-2.28100Analyst ForecastInsider TradeHigh Trading VolumeCDTXCidara Therapeutics4.1659 of 5 stars$48.30-1.0%$57.14+18.3%+311.9%$983.59M$1.27M-1.6490Positive NewsHigh Trading VolumeCOLLCollegium Pharmaceutical4.2823 of 5 stars$30.90+1.8%$43.75+41.6%+0.7%$975.20M$631.45M25.33210Buyback AnnouncementBGMBGM GroupN/A$10.00-0.3%N/AN/A$975.14M$25.10M0.00298PHVSPharvaris1.5283 of 5 stars$18.00-3.2%$36.20+101.1%+28.7%$972.60MN/A-5.9830 Related Companies and Tools Related Companies Aurinia Pharmaceuticals Alternatives Ardelyx Alternatives Enliven Therapeutics Alternatives Verve Therapeutics Alternatives Niagen Bioscience Alternatives Dyne Therapeutics Alternatives Cidara Therapeutics Alternatives Collegium Pharmaceutical Alternatives BGM Group Alternatives Pharvaris Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRVS Stock Alerts